ClinicalTrials.Veeva

Menu

Cardiovascular Biomarkers and Lung Edema in Severe Burns Patients (CAROLE)

P

Paris Hospitals Public Assistance (APHP)

Status

Unknown

Conditions

Burns

Study type

Observational

Funder types

Other

Identifiers

NCT03271268
StLouisFrance

Details and patient eligibility

About

Burn injury leads to hypovolemic then distributive shock. Fluid resuscitation remains the cornerstone of initial treatment of burn shock. However, fluid rescucitation can lead to fluid overload, which manifests most notably as lung edema.

The peptide NT-pro-BNP, a biomarker of cardiac congestion secreted by the myocardium, as well as plasma CD146, an endothelial factor involved in angiogenesis and a marker of vascular congestion, may help identifying patients with risk of pulmonary edema and hypoxia .

Our hypothesis is that these biomarkers may predict the occurence of pulmonary edema in severe burns patients.

Enrollment

36 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Intubated mechanically-ventilated patients within the first 24 hours of admission
  • And/or patients with total body surface area (TBSA) burn-injured >20 %
  • And/or patients with at least 10% full-thickness burns
  • And/or receiving vasopressors within the first 24 hours of admission
  • And monitored by a PiCCO system (PiCCO-2 Pulsion Medical Systems AG, Munich, Germany)

Exclusion criteria

  • Admission delay to ICU > 24 hours post burn
  • Age less than 18 years
  • Pregnancy
  • Chronic renal impairment with a baseline eGFR < 15 ml/min
  • Patients with chemical or electrical burns
  • Coexisting non-burn trauma
  • Patients moribund on admission or dead within 72 h from admission
  • Patients with do-not-resuscitate orders

Trial contacts and locations

1

Loading...

Central trial contact

Sabri Soussi, MD; Matthieu Legrand, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems